Farmacia italiana online: acquisto cialis in Italia e Roma senza ricetta.
Microsoft word - ibis-ii hunter media release.doc
Australian New Zealand Breast Cancer Trials Group
16 APRIL 2010
100th Hunter Woman Joins Life-Saving Breast Cancer Prevention Study
IBIS-II, a major international breast cancer prevention study, has reached an important
milestone with 100 women from the Hunter region volunteering to take part. However, many
more volunteers are needed to help reach the international goal of 10,000 women.
IBIS-II is being conducted in Australia and New Zealand by the Australian New Zealand Breast
Cancer Trials Group (ANZ BCTG) and is coordinated internationally by Cancer Research UK. It
is the second prevention study undertaken by the ANZ BCTG and follows the landmark IBIS-I
study, which showed that the drug tamoxifen could prevent breast cancer in some women at
The new, unique and vitally important IBIS-II study is supported in Australia and New Zealand by
the National Health and Medical Research Council. It is the only clinical trial worldwide to
investigate whether the drug anastrozole can prevent breast cancer in postmenopausal women
who are at increased risk of the disease.
Previous research using anastrozole as a treatment for early breast cancer suggests that it could
prevent up to 70 percent of new tumours occurring, or 300,000 breast cancers per year,
worldwide. To confirm its role in preventing the disease in women at increased risk, a large
comparative outcomes study must be conducted. More women are encouraged to participate so
that the results are obtained as soon as possible.
Elizabeth Doyle from Cardiff, NSW was recently the 100th woman to join IBIS-II through Calvary
Mater Newcastle. She is taking part in the study to help change the lives of women in the future.
“My mother died of breast cancer at age 78, when I was 37,” Elizabeth said. “We had a
wonderful relationship, she was my best friend, and I feel I have missed out on what could have
been quite a few more years of having her in my life.”
“The IBIS-II study may or may not necessarily help me but if I can help other women to perhaps
have their mothers, daughters, sisters or nieces in their lives longer, then to me that would be so
wonderful. If any other women are considering joining the study I encourage them to do it
because it is so important that we do everything we can to fight, and win, against this disease.”
Professor John Forbes, ANZ BCTG Director of Research, Professor of Surgical Oncology at the
University of Newcastle and International IBIS-II Study Co-Chairman said it was very gratifying
that so many women had come forward to take part in the IBIS-II study.
“The findings from this research could provide a valuable approach to prevent breast cancer, not
only for women today but also for their daughters and granddaughters in the future.”
“This study represents a remarkable collaboration by the researchers of the ANZ BCTG with
their international colleagues and highlights the important contribution being made by women in
Australia and New Zealand that may ultimately provide benefit globally for millions of women.”
Hunter women can find out more about whether they are eligible to take part in the study by
calling 1800 640 709
. More information is also available on the ANZ BCTG website: www.anzbctg.org
To interview Professor Forbes or a woman taking part in the study, please contact:
Katie Smith - Recruitment and Promotions Officer, ANZ BCTG.
Ph: +61 2 4985 0134 / 0412 675 382
NOTES TO EDITORS:
About IBIS-II (International Breast cancer Intervention Study II)
IBIS-II is being coordinated in Australia and New Zealand by the Australian New Zealand Breast Cancer
Trials Group and globally by Cancer Research UK. The trial is taking place in 21 countries including
Australia, New Zealand, India, Chile, Germany, Italy and the United Kingdom. Over 5,300 women have
joined worldwide – more than half of the international goal of 10,000 women.
IBIS-II was launched in Australia and New Zealand in 2005 and now involves 34 institutions and more
than 630 women contributing an important 12% of the global recruitment total so far.
More than 2,500 women in New Zealand and 12,000 women in Australia are diagnosed with breast cancer
every year. Mortality has fallen due to improvements in the treatment of breast cancer, and more cancers
are being diagnosed early through national screening programmes when the chance of cure is highest.
However, there are many important research questions yet to be answered, and learning more about how
breast cancer can be prevented is one of these.
• The IBIS-II Prevention part of the study aims to recruit 6,000 postmenopausal women who are at
increased risk of developing breast cancer. A number of factors for increased risk can make a woman eligible to enter the study and these are set according to the different age groups. Women can take part in the trial if they are aged between 40 and 70 years and are not on HRT.
• IBIS-II DCIS aims to recruit 4,000 postmenopausal women who have been diagnosed with, and
had surgery to remove, Ductal Carcinoma in Situ (DCIS). This part of the trial is designed to determine which of the two drugs, anastrozole or tamoxifen, can best prevent new cancers, both in the breast affected by DCIS and in the opposite breast. Women who have had a mastectomy to remove their DCIS cannot join this arm of the trial but they can be part of IBIS-II Prevention.
• Further information on IBIS-II is available at www.anzbctg.org.
• In Australia women can obtain more information on IBIS-II by telephoning 1800 640 709. New
About the Australian New Zealand Breast Cancer Trials Group
The Australian New Zealand Breast Cancer Trials Group (ANZ BCTG) is Australia’s only collaborative,
independent breast cancer clinical trials research group. It is dedicated to the cure and prevention of
breast cancer through the conduct of multi-institution and international clinical trials. Working in
collaboration with 500 researchers in more than 80 of the leading medical institutions in Australia and New
Zealand, and with similar research groups internationally, ensures Australia and New Zealand are at the
forefront of breast cancer research progress and this delivers benefits to women immediately. Additional
information can be found at www.anzbctg.org.
ANZ Breast Cancer Trials Group Limited, Department of Surgical Oncology
University of Newcastle, Locked Bag 7, Hunter Region Mail Centre NSW 2310 AUSTRALIA
Ph: (02) 4985 0134 Fax: (02) 4985 0140 Email: firstname.lastname@example.org
WAYNE MEMORIAL HOSPITAL CAMPUS MEDICAL OFFICE BUILDING SECTION 230516 - EXPANSION FITTINGS AND LOOPS FOR HVAC PIPING Drawings and general provisions of the Contract, including General and Supplementary Conditions and Division 01 Specification Sections, apply to this Section. 3. Pipe loops, offsets, and swing joints A. ASTM A 269 - Standard Specification for Seamless and Welded Austeniti
Innovative Romanian Food Biotechnology © 2007 by “Dunărea de Jos” University – Galaţi Received July 24, 2007 / Accepted September 26, 2007 RESEARCH ARTICLE BIOREMEDIATION OF PHENOL USING MICROBIAL CONSORTIUM IN BIOREACTOR Dipty SINGH and M. H. FULEKAR1* 1Professor & Head Department of Life Sciences, University of Mumbai, Vidyanagari Campus, Santacruz (E) Mumba